6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents

Structurally unique 6,7-seco-ent-kaurenes, which are widely distributed in the genus Isodon, have attracted considerable attention because of their antitumor activities. Previously, a convenient conversion of commercially available oridonin (1) to 6,7-seco-ent-kaurenes was developed. Herein, several...

Full description

Bibliographic Details
Main Authors: Xu, Shengtao, Yao, Hong, Hu, Mei, Li, Dahong, Zhu, Zheying, Xie, Weijia, Yao, Hequan, Wu, Liang, Chen, Zhe-Sheng, Xu, Jinyi
Format: Article
Published: American Chemical Society 2017
Online Access:https://eprints.nottingham.ac.uk/46459/
_version_ 1848797331833487360
author Xu, Shengtao
Yao, Hong
Hu, Mei
Li, Dahong
Zhu, Zheying
Xie, Weijia
Yao, Hequan
Wu, Liang
Chen, Zhe-Sheng
Xu, Jinyi
author_facet Xu, Shengtao
Yao, Hong
Hu, Mei
Li, Dahong
Zhu, Zheying
Xie, Weijia
Yao, Hequan
Wu, Liang
Chen, Zhe-Sheng
Xu, Jinyi
author_sort Xu, Shengtao
building Nottingham Research Data Repository
collection Online Access
description Structurally unique 6,7-seco-ent-kaurenes, which are widely distributed in the genus Isodon, have attracted considerable attention because of their antitumor activities. Previously, a convenient conversion of commercially available oridonin (1) to 6,7-seco-ent-kaurenes was developed. Herein, several novel spiro-lactone-type ent-kaurene derivatives bearing various substituents at the C-1 and C-14 positions were further designed and synthesized from the natural product oridonin. Moreover, a number of seven-membered C-ring-expanded 6,7-seco-ent-kaurenes were also identified for the first time. It was observed that most of the spiro-lactone-type ent-kaurenes tested markedly inhibited the proliferation of cancer cells, with an IC50 value as low as 0.55 μM. An investigation on its mechanism of action showed that the representative compound 7b affected the cell cycle and induced apoptosis at a low micromolar level in MCF-7 human breast cancer cells. Furthermore, compound 7b inhibited liver tumor growth in an in vivo mouse model and exhibited no observable toxic effects. Collectively, the results warrant further preclinical investigations of these spiro-lactone-type ent-kaurenes as potential novel anticancer agents.
first_indexed 2025-11-14T20:02:11Z
format Article
id nottingham-46459
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T20:02:11Z
publishDate 2017
publisher American Chemical Society
recordtype eprints
repository_type Digital Repository
spelling nottingham-464592020-05-04T19:06:07Z https://eprints.nottingham.ac.uk/46459/ 6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents Xu, Shengtao Yao, Hong Hu, Mei Li, Dahong Zhu, Zheying Xie, Weijia Yao, Hequan Wu, Liang Chen, Zhe-Sheng Xu, Jinyi Structurally unique 6,7-seco-ent-kaurenes, which are widely distributed in the genus Isodon, have attracted considerable attention because of their antitumor activities. Previously, a convenient conversion of commercially available oridonin (1) to 6,7-seco-ent-kaurenes was developed. Herein, several novel spiro-lactone-type ent-kaurene derivatives bearing various substituents at the C-1 and C-14 positions were further designed and synthesized from the natural product oridonin. Moreover, a number of seven-membered C-ring-expanded 6,7-seco-ent-kaurenes were also identified for the first time. It was observed that most of the spiro-lactone-type ent-kaurenes tested markedly inhibited the proliferation of cancer cells, with an IC50 value as low as 0.55 μM. An investigation on its mechanism of action showed that the representative compound 7b affected the cell cycle and induced apoptosis at a low micromolar level in MCF-7 human breast cancer cells. Furthermore, compound 7b inhibited liver tumor growth in an in vivo mouse model and exhibited no observable toxic effects. Collectively, the results warrant further preclinical investigations of these spiro-lactone-type ent-kaurenes as potential novel anticancer agents. American Chemical Society 2017-09-13 Article PeerReviewed Xu, Shengtao, Yao, Hong, Hu, Mei, Li, Dahong, Zhu, Zheying, Xie, Weijia, Yao, Hequan, Wu, Liang, Chen, Zhe-Sheng and Xu, Jinyi (2017) 6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents. Journal of Natural Products . ISSN 1520-6025 http://pubs.acs.org/doi/abs/10.1021/acs.jnatprod.7b00057 doi:10.1021/acs.jnatprod.7b00057 doi:10.1021/acs.jnatprod.7b00057
spellingShingle Xu, Shengtao
Yao, Hong
Hu, Mei
Li, Dahong
Zhu, Zheying
Xie, Weijia
Yao, Hequan
Wu, Liang
Chen, Zhe-Sheng
Xu, Jinyi
6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents
title 6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents
title_full 6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents
title_fullStr 6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents
title_full_unstemmed 6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents
title_short 6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents
title_sort 6,7-seco-ent-kauranoids derived from oridonin as potential anticancer agents
url https://eprints.nottingham.ac.uk/46459/
https://eprints.nottingham.ac.uk/46459/
https://eprints.nottingham.ac.uk/46459/